Product Jurisdiction
Establishes how FDA determines which Center has primary jurisdiction over a product, using the primary mode of action, and sets out the Request for Designation procedure by which a sponsor obtains a formal determination when the classification is unclear.
Always verify against the current published text before relying on it for a submission or inspection.
Scope & applicability
Products whose regulatory classification is not self-evident — combination products, and any article that could be a drug, device, or biological product depending on how its principal intended effect is achieved. It decides the Center and therefore the entire downstream regime; it does not itself impose manufacturing requirements, which come from 21 CFR Part 4 and the constituent-part regulations.
Key requirements
- Classification driven by the primary mode of action — the single mode of action expected to make the greatest contribution to the overall intended therapeutic effect
- Request for Designation as the formal route to a binding jurisdictional determination
- Defined FDA response period following a complete Request for Designation
- Assignment of an agency component with primary jurisdiction, and of consulting components
Implementation tips
- Reason the classification from the intended use and mechanism actually claimed, not from a competitor product that looks similar — the claim is what FDA reads
- Where the primary mode of action is genuinely uncertain, a Request for Designation is cheaper than discovering the answer at submission
21 CFR Part 3: frequently asked questions
Quick answers to common questions about 21 CFR Part 3.
What is 21 CFR Part 3?
21 CFR Part 3 — Product Jurisdiction — is a regulation issued by the Food and Drug Administration (United States). Establishes how FDA determines which Center has primary jurisdiction over a product, using the primary mode of action, and sets out the Request for Designation procedure by which a sponsor obtains a formal determination when the classification is unclear.
Who does 21 CFR Part 3 apply to?
Products whose regulatory classification is not self-evident — combination products, and any article that could be a drug, device, or biological product depending on how its principal intended effect is achieved. It decides the Center and therefore the entire downstream regime; it does not itself impose manufacturing requirements, which come from 21 CFR Part 4 and the constituent-part regulations.
What are the key requirements of 21 CFR Part 3?
FDA 21 CFR Part 3 requires, among other things: Classification driven by the primary mode of action — the single mode of action expected to make the greatest contribution to the overall intended therapeutic effect; Request for Designation as the formal route to a binding jurisdictional determination; Defined FDA response period following a complete Request for Designation; Assignment of an agency component with primary jurisdiction, and of consulting components.
When was 21 CFR Part 3 last updated?
The current version of 21 CFR Part 3 dates from November 1991.